financetom
Business
financetom
/
Business
/
Nasdaq, Cboe Challenge New SEC Rules Intended to Boost Market Transparency
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Nasdaq, Cboe Challenge New SEC Rules Intended to Boost Market Transparency
Nov 4, 2024 11:46 AM

05:17 PM EDT, 10/31/2024 (MT Newswires) -- Nasdaq (NDAQ) and Cboe Global Markets ( CBOE ) are challenging recent changes in US stock market rules intended to help investors better understand the costs they pay to trade stocks and other securities.

The US Securities and Exchange Commission in September adopted revisions to its national markets system regulations lowering the maximum price securities exchanges charge for market access while also helping investors find the best available price for those costs, particularly with smaller-sized transactions.

Nasdaq and Cboe and other plaintiffs in the case pending in the US Court of Appeals for the Federal Circuit in Washington, D.C., argue the new rules will significantly increase their cost of doing business.

The story was earlier reported by Bloomberg. Cboe told the news outlet that the revised rules fall short of their intended effect and "will inhibit price discovery," leading them to petition a review.

Neither Nasdaq, Cboe nor the SEC immediately returned messages from MT Newswires.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Bristol-Myers Squibb Says Applications for Opdivo Accepted by US, European Regulators
Bristol-Myers Squibb Says Applications for Opdivo Accepted by US, European Regulators
May 6, 2024
07:58 AM EDT, 05/06/2024 (MT Newswires) -- Bristol-Myers Squibb ( BMY ) said Monday that separate applications for Opdivo have been accepted by the US Food and Drug Administration and the European Medicines Agency. The FDA has accepted the biologics license application for the subcutaneous formulation of Opdivo co-formulated with Halozyme's recombinant human hyaluronidase while the EMA has validated the...
Jones Lang LaSalle's Q1 Adjusted Earnings, Revenue Climb
Jones Lang LaSalle's Q1 Adjusted Earnings, Revenue Climb
May 6, 2024
07:59 AM EDT, 05/06/2024 (MT Newswires) -- Jones Lang LaSalle ( JLL ) reported Q1 adjusted earnings Monday of $1.78 per diluted share, up from $0.71 a year earlier. Analysts polled by Capital IQ expected $0.86. Revenue for the quarter ended March 31 was $5.12 billion, up from $4.72 billion a year earlier. Analysts polled by Capital IQ expected $4.82...
Top Premarket Decliners
Top Premarket Decliners
May 6, 2024
07:57 AM EDT, 05/06/2024 (MT Newswires) -- Meta Materials ( MMAT ) shares slumped 30% Monday premarket after the company said late Friday its board approved to reduce its workforce by about 80%. Medical Properties Trust ( MPW ) shares fell 15% following a muted session. Mobile-Health Network Solutions ( MNDR ) shares were down 14%, extending Friday's slide. Price:...
Alpha Metallurgical Resources' Q1 Earnings, Revenue Decline
Alpha Metallurgical Resources' Q1 Earnings, Revenue Decline
May 6, 2024
07:58 AM EDT, 05/06/2024 (MT Newswires) -- Alpha Metallurgical Resources ( AMR ) reported Q1 net income Monday of $9.59 per diluted share, down from $17.01 a year earlier. Two analysts polled by Capital IQ expected $10.83. Revenue for mining company for the quarter ended March 31 was $864.1 million, compared with $911.2 million a year earlier. Two analysts surveyed...
Copyright 2023-2026 - www.financetom.com All Rights Reserved